Interleukin 12 immunotherapy after autologous stem cell transplantation for hematological malignancies

Michael Robertson, David Pelloso, Rafat Abonour, Robert A. Hromas, Robert Nelson, Lisa Wood, Kenneth Cornetta

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Purpose: To determine the safety, maximum tolerated dose, and biological effects of recombinant human IL-12 after autologous stem cell transplantation for cancer. Experimental Design: Twelve patients with hematological malignancies (8 non-Hodgkin's lymphoma, 2 Hodgkin's disease, and 2 plasma cell myeloma) began interleukin (IL)-12 therapy at a median of 66 days after transplantation. Recombinant human IL-12 was given by bolus i.v. injection in doses of 30, 100, or 250 ng/kg once as an inpatient and then, after a 2-week hiatus, once daily for 5 consecutive days every 3 weeks on an outpatient basis. Results: Common side effects included fever, chills, fatigue, nausea or vomiting, and asymptomatic elevation in serum liver function tests. Transient neutropenia and thrombocytopenia were also common, but no patient required platelet transfusion or had a neutropenic fever. Dose-limiting toxicities (diarrhea and elevated liver function tests) occurred in 2 of 3 patients treated in the 250 ng/kg cohort. Biological effects, including increases in serum IFN-γ levels and transient lymphopenia involving CD4 T cells, CD8 T cells, B cells, and NK cells, were seen at all three dose levels. Conclusions: Biologically active doses of IL-12 can be given safely to patients after autologous stem cell transplantation for high-risk hematological malignancies. Further studies are indicated to assess the efficacy of IL-12 in this setting.

Original languageEnglish
Pages (from-to)3383-3393
Number of pages11
JournalClinical Cancer Research
Volume8
Issue number11
StatePublished - Nov 1 2002

Fingerprint

Stem Cell Transplantation
Hematologic Neoplasms
Interleukin-12
Immunotherapy
Liver Function Tests
Fever
T-Lymphocytes
Platelet Transfusion
Chills
Lymphopenia
Maximum Tolerated Dose
Neutropenia
Serum
Multiple Myeloma
Hodgkin Disease
Natural Killer Cells
Thrombocytopenia
Non-Hodgkin's Lymphoma
Nausea
Vomiting

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Interleukin 12 immunotherapy after autologous stem cell transplantation for hematological malignancies. / Robertson, Michael; Pelloso, David; Abonour, Rafat; Hromas, Robert A.; Nelson, Robert; Wood, Lisa; Cornetta, Kenneth.

In: Clinical Cancer Research, Vol. 8, No. 11, 01.11.2002, p. 3383-3393.

Research output: Contribution to journalArticle

@article{e4f1298b69f3409691e4715d213eb97d,
title = "Interleukin 12 immunotherapy after autologous stem cell transplantation for hematological malignancies",
abstract = "Purpose: To determine the safety, maximum tolerated dose, and biological effects of recombinant human IL-12 after autologous stem cell transplantation for cancer. Experimental Design: Twelve patients with hematological malignancies (8 non-Hodgkin's lymphoma, 2 Hodgkin's disease, and 2 plasma cell myeloma) began interleukin (IL)-12 therapy at a median of 66 days after transplantation. Recombinant human IL-12 was given by bolus i.v. injection in doses of 30, 100, or 250 ng/kg once as an inpatient and then, after a 2-week hiatus, once daily for 5 consecutive days every 3 weeks on an outpatient basis. Results: Common side effects included fever, chills, fatigue, nausea or vomiting, and asymptomatic elevation in serum liver function tests. Transient neutropenia and thrombocytopenia were also common, but no patient required platelet transfusion or had a neutropenic fever. Dose-limiting toxicities (diarrhea and elevated liver function tests) occurred in 2 of 3 patients treated in the 250 ng/kg cohort. Biological effects, including increases in serum IFN-γ levels and transient lymphopenia involving CD4 T cells, CD8 T cells, B cells, and NK cells, were seen at all three dose levels. Conclusions: Biologically active doses of IL-12 can be given safely to patients after autologous stem cell transplantation for high-risk hematological malignancies. Further studies are indicated to assess the efficacy of IL-12 in this setting.",
author = "Michael Robertson and David Pelloso and Rafat Abonour and Hromas, {Robert A.} and Robert Nelson and Lisa Wood and Kenneth Cornetta",
year = "2002",
month = "11",
day = "1",
language = "English",
volume = "8",
pages = "3383--3393",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - Interleukin 12 immunotherapy after autologous stem cell transplantation for hematological malignancies

AU - Robertson, Michael

AU - Pelloso, David

AU - Abonour, Rafat

AU - Hromas, Robert A.

AU - Nelson, Robert

AU - Wood, Lisa

AU - Cornetta, Kenneth

PY - 2002/11/1

Y1 - 2002/11/1

N2 - Purpose: To determine the safety, maximum tolerated dose, and biological effects of recombinant human IL-12 after autologous stem cell transplantation for cancer. Experimental Design: Twelve patients with hematological malignancies (8 non-Hodgkin's lymphoma, 2 Hodgkin's disease, and 2 plasma cell myeloma) began interleukin (IL)-12 therapy at a median of 66 days after transplantation. Recombinant human IL-12 was given by bolus i.v. injection in doses of 30, 100, or 250 ng/kg once as an inpatient and then, after a 2-week hiatus, once daily for 5 consecutive days every 3 weeks on an outpatient basis. Results: Common side effects included fever, chills, fatigue, nausea or vomiting, and asymptomatic elevation in serum liver function tests. Transient neutropenia and thrombocytopenia were also common, but no patient required platelet transfusion or had a neutropenic fever. Dose-limiting toxicities (diarrhea and elevated liver function tests) occurred in 2 of 3 patients treated in the 250 ng/kg cohort. Biological effects, including increases in serum IFN-γ levels and transient lymphopenia involving CD4 T cells, CD8 T cells, B cells, and NK cells, were seen at all three dose levels. Conclusions: Biologically active doses of IL-12 can be given safely to patients after autologous stem cell transplantation for high-risk hematological malignancies. Further studies are indicated to assess the efficacy of IL-12 in this setting.

AB - Purpose: To determine the safety, maximum tolerated dose, and biological effects of recombinant human IL-12 after autologous stem cell transplantation for cancer. Experimental Design: Twelve patients with hematological malignancies (8 non-Hodgkin's lymphoma, 2 Hodgkin's disease, and 2 plasma cell myeloma) began interleukin (IL)-12 therapy at a median of 66 days after transplantation. Recombinant human IL-12 was given by bolus i.v. injection in doses of 30, 100, or 250 ng/kg once as an inpatient and then, after a 2-week hiatus, once daily for 5 consecutive days every 3 weeks on an outpatient basis. Results: Common side effects included fever, chills, fatigue, nausea or vomiting, and asymptomatic elevation in serum liver function tests. Transient neutropenia and thrombocytopenia were also common, but no patient required platelet transfusion or had a neutropenic fever. Dose-limiting toxicities (diarrhea and elevated liver function tests) occurred in 2 of 3 patients treated in the 250 ng/kg cohort. Biological effects, including increases in serum IFN-γ levels and transient lymphopenia involving CD4 T cells, CD8 T cells, B cells, and NK cells, were seen at all three dose levels. Conclusions: Biologically active doses of IL-12 can be given safely to patients after autologous stem cell transplantation for high-risk hematological malignancies. Further studies are indicated to assess the efficacy of IL-12 in this setting.

UR - http://www.scopus.com/inward/record.url?scp=0036847429&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036847429&partnerID=8YFLogxK

M3 - Article

C2 - 12429625

AN - SCOPUS:0036847429

VL - 8

SP - 3383

EP - 3393

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 11

ER -